<DOC>
	<DOCNO>NCT01191892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Vandetanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether give carboplatin gemcitabine hydrochloride effective without vandetanib first-line therapy treat urinary tract cancer . PURPOSE : This randomized phase II trial study give carboplatin together gemcitabine hydrochloride see well work give without vandetanib first-line therapy treat patient locally advance metastatic urinary tract cancer .</brief_summary>
	<brief_title>Carboplatin Gemcitabine Hydrochloride With Without Vandetanib First-Line Therapy Treating Patients With Locally Advanced Metastatic Urinary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine antitumor activity ( measure progression-free survival ) carboplatin gemcitabine hydrochloride versus without vandetanib first-line treatment patient locally advance metastatic urothelial cell cancer suitable receive cisplatin . Secondary - To determine safety , feasibility , tolerability regimens patient . - To determine objective response rate . - To determine overall survival patient treat regimen - To assess change size measurable lesion 9 week study therapy . OUTLINE : This multicenter study . Patients stratify accord relevant factor . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carboplatin IV 30 minute day 1 , gemcitabine hydrochloride IV 30 minute day 1 8 , oral placebo daily day 1-21 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patient receive carboplatin gemcitabine hydrochloride arm I . Patients also receive oral vandetanib daily day 1-21 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Blood urine sample may collect laboratory analysis baseline completion study . After completion study treatment , patient follow week 18 , 26 , 39 , 52 . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma ( pure mixed histology ) urothelium ( upper low urinary tract ) Cancers pathology permit provided dominant morphology transitional cell carcinoma Radiologically measurable disease accord RECIST v 1.1 criterion Locally advance and/or metastatic disease amenable curative treatment surgery radiotherapy Patient suitable cisplatin therapy , meet 1 follow criterion : More 75 year age ECOG performance status &gt; 2 Creatinine clearance &lt; 30 mL/min Clinically significant ischemic heart disease ( myocardial infarction unstable angina 3 less 12 month prior date randomization , symptomatic angina , NYHA class I within 3 month prior date randomization ) Prior intolerance cisplatin Any factor , opinion investigator , indicate cisplatin suitable patient ( e.g. , unilateral hearing loss ) PATIENT CHARACTERISTICS : See Disease Characteristics ECOG performance status 02 Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 30 mL/min Potassium ≥ 4.0 mmol/L OR CTCAE grade 1 upper limit Magnesium normal OR CTCAE grade 1 upper limit Serum calcium ≤ 2.9 mmol/L ( If serum calcium &lt; low limit normal [ LLN ] , adjust serum calcium must ≥ LLN ) ALT/AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN ( &lt; 5 time ULN judge investigator relate liver metastasis ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective barriermethod contraception 3 month ( woman ) 2 month ( men ) completion study therapy No evidence severe uncontrolled systemic disease concurrent condition , investigator 's opinion , make undesirable patient participate trial would jeopardize compliance protocol No significant risk cardiac complication , define follow : Clinically significant cardiovascular event ( e.g. , myocardial infarction , superior vena cava syndrome [ SVC ] , NYHA classification heart disease ≥ class II within 3 month prior entry , presence cardiac disease , opinion investigator , significantly increase risk ventricular arrhythmia ) History arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia Atrial fibrillation , control medication , exclusionary No QTc prolongation medication require discontinuation medication No congenital long QT syndrome firstdegree relative unexplained sudden death 40 year age No QTc immeasurable ≥ 480 msec screen ECG If patient QTc interval ≥ 480 msec screen ECG , ECG screen may repeat twice ( least 24 hour apart ) average QTc three screen ECGs must &lt; 480 msec order patient eligible study Patients receive drug risk Torsades de Pointes exclude QTc ≥ 460 msec No presence leave bundle branch block No hypertension control medical therapy ( systolic blood pressure &gt; 160 mm Hg diastolic blood pressure &gt; 100 mm Hg ) No currently active diarrhea , investigator 's opinion , may affect ability patient either absorb vandetanib tolerate additional diarrhea episodes No previous current malignancy histology within past 5 year except carcinoma situ cervix , adequately treat basal cell squamous cell carcinoma skin , prostate cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior concurrent know potent CYP3A4 inducer ( e.g. , barbiturate , rifampicin , rifabutin , phenytoin , carbamazepine , troglitazone , phenobarbital , St. John wort ) medication know adverse interaction vandetanib Dexamethasone ( equivalent ) allow premedication chemotherapy At least 4 week since prior major surgery complete surgical wound heal At least 30 day since prior concurrent investigational agent No prior chemotherapy ( unless deliver perioperatively complete &gt; 12 month prior first presentation recurrent disease ) No concurrent anticancer drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>ureter cancer</keyword>
</DOC>